Filing Flows › Altria Group (MO) › Q3 2026 › vs Q2 2026
Altria Group (MO) Q3 2026 vs Q2 2026 (quarter over quarter)
Altria Group's revenue rose $21.0M (+0.3%) from $6.1B in Q2 2026 to $6.1B in Q3 2026. The biggest changes: Smokeable Products Segment +$40.0M (+0.7%); Oral Tobacco Segment −$25.0M (-4%); All Other +$6.0M (+100%). Gross margin 64.3% against 62.5% (+1.8 pts).
Altria Group, Q3 2026: revenue $6.1B (+1% year over year), operating margin 54.0%, net earnings $2.5B, operating cash flow $3.1B. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Gross margin | 64.3% | 62.5% | +1.8 pts |
| Operating margin | 54.0% | 51.3% | +2.7 pts |
| Net margin | 41.0% | 37.6% | +3.4 pts |
| Free cash flow margin | 48.9% | 10.8% | +38.1 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Smokeable Products Segment | $5.4B | $5.4B | $40.0M | +0.7% |
| Oral Tobacco Segment | $688M | $713M | −$25.0M | -4% |
| All Other | $12.0M | $6.0M | $6.0M | +100% |
| Revenue | $6.1B | $6.1B | $21.0M | +0.3% |
| Gross profit | $3.9B | $3.8B | $121M | +3% |
| Cost of revenue | $2.2B | $2.3B | −$100M | -4% |
| Operating profit | $3.3B | $3.1B | $177M | +6% |
| Operating expenses | $628M | $684M | −$56.0M | -8% |
| Pre-tax earnings | $3.3B | $2.9B | $361M | +12% |
| Other expense, net | $23.0M | $207M | −$184M | -89% |
| Net earnings | $2.5B | $2.3B | $216M | +9% |
| Income tax | $776M | $631M | $145M | +23% |
| Depreciation & amortization | $60.0M | $56.0M | $4.0M | +7% |
| Working capital & other | $534M | −$1.6B | $2.2B | — |
| Operating cash flow | $3.1B | $719M | $2.4B | +332% |
| Free cash flow (OCF − capex) | $3.0B | $662M | $2.3B | +353% |
| Capital expenditures | $109M | $57.0M | $52.0M | +91% |
Questions
How much did Altria Group's revenue grow quarter over quarter in Q3 2026?
Altria Group's revenue rose $21.0M (+0.3%) from $6.1B in Q2 2026 to $6.1B in Q3 2026.
What drove Altria Group's revenue change in Q3 2026?
Smokeable Products Segment +$40.0M (+0.7%); Oral Tobacco Segment −$25.0M (-4%); All Other +$6.0M (+100%).